T. Rowe Price國際股票主動型ETF TOUS 深 滬
已收盤 05-15 16:00:00 美东时间
36.465
-0.765
-2.05%
華盛通- 最 高36.64
- 今 開36.64
- 成交量 14.84万股
- 最 低 36.43
- 昨 收 37.23
- 總市值 140.57万
- 52周最高 38.17
- 市盈率 靜 --
- 換手率 384.98%
- 52周最低 30.3898
- 委 比 0.00%
- 總股本 3.86万
- 歷史最高 38.17
- 量 比 0.43
- 振 幅 0.56%
- 歷史最低 20.8469
- 每 手 1
- 風險率 2.07%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Dow Futures Sink Over 450 Points, Oil Reaches $90 Again; Trump Says Marines Took Custody Of Iranian Ship, Tehran Rejects Negotiations
U.S. stock futures tumbled while oil surged above $90 after Donald Trump said Marines seized an Iranian-linked ship.
04-20 09:46
美伊局势追踪：特朗普二轮和谈邀约“遭拒” 美军开火、伊朗誓言报复
①美国总统特朗普称美国代表将赴伊斯兰堡参加第二轮美伊谈判，但伊朗方面否认这一消息，并指责美国在谈判中提出不合理要求，频繁改变立场，且持续进行海上封锁； ②美军在阿曼湾向一艘伊朗商船开火，并控制该船，伊朗武装部队誓言将对美军的海盗行径进行回应和报复。
04-20 08:07
Trump says U.S. Navy seized sanctioned Iranian-flagged ship in Gulf of Oman
President Donald Trump said Sunday that the U.S. Navy intercepted and boarded an Iranian-flagged cargo vessel in the Gulf of Oman after the ship allegedly ignored repeated orders to stop. President ...
04-20 03:56
BRIEF-Recursion to Host Webinar on Tupelo Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis on Dec. 8
Dec 1 (Reuters) - Recursion Pharmaceuticals Inc RXRX.O: RECURSION ANNOUNCES WEBINAR FOR UPCOMING CLINICAL DATA READOUT ON THE TUPELO PHASE 1B/2 TRIAL OF REC-4881 IN FAMILIAL ADENOMATOUS POLYPOSIS ON D...
2025-12-01 21:50
King Charles heads to Canada in show of support for realm eyed by Trump
British monarch to open Canadian parliament on two-day visit Charles has subtly backed Canada during Trump's ambitions Faces tricky balancing act as British PM Starmer courts Trump Charles to travel w...
2025-05-26 14:00
BRIEF-Tempest gets FDA nod to begin mid-stage study of its therapy for colon cancer-causing genertic condition
March 13 (Reuters) - Tempest Therapeutics Inc TPST.O: FDA STUDY MAY PROCEED NOTICE RECEIVED FOR PHASE 2 TRIAL OF TPST-1495 FOR THE TREATMENT OF FAMILIAL ADENOMATOUS POLYPOSIS (FAP) TEMPEST THERAPEUTIC...
2025-03-13 20:20
BRIEF-Ensoma Receives Rare Pediatric Disease And Orphan Drug Designations For EN-374 For Treatment Of Chronic Granulomatous Disease
Feb 13 (Reuters) - ENSOMA RECEIVES RARE PEDIATRIC DISEASE AND ORPHAN DRUG DESIGNATIONS FOR EN-374 FOR TREATMENT OF CHRONIC GRANULOMATOUS DISEASE Source text: ID:nBw53H6sZa Further company coverage: [ ...
2025-02-13 20:06
